
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

(Rule 13d-101)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT
TO RULE 13d-2(a)
(Amendment No. 16)***

Aceragen, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share
(Title of Class of Securities)

00445F109
(CUSIP number)

Youssef El Zein
c/o Stuarts Corporate Services Ltd.
Kensington House, 69 Dr. Roy's Drive
Georgetown, Grand Cayman KY1-1104
Cayman Islands

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 13, 2023
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ☐.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

1.	NAMES OF REPORTING PERSONS	
	Pillar Pharmaceuticals 6, L.P.	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3.	SEC USE ONLY	
4.	SOURCE OF FUNDS*	
	WC	
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)	
	<input type="checkbox"/>	
6.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Cayman Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7.	SOLE VOTING POWER
		0
	8.	SHARED VOTING POWER
		571,588 (1)
	9.	SOLE DISPOSITIVE POWER
		0
	10.	SHARED DISPOSITIVE POWER
		571,588 (1)
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	571,588 (1)	
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
	<input type="checkbox"/>	
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11	
	6.7% (2)	
14.	TYPE OF REPORTING PERSON	
	PN	

- (1) This Amendment No. 16 (as defined below) to Schedule 13D (as defined below) is filed by Pillar Pharmaceuticals 6, L.P. (“Pillar 6”), Pillar Invest Corporation (“Pillar GP”), Pillar Partners Foundation, L.P. (“Pillar Foundation”, and, together with Pillar 6 and Pillar GP, the “Pillar Entities”), Abude Umari and Youssef El Zein (together with the Pillar Entities and Mr. Umari, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Amendment No. 16 to Schedule 13D. The Pillar Entities exercise no voting or dispositive power over and expressly disclaim beneficial ownership of any shares of the common stock, par value \$0.001 per share (the “Common Stock”), of Aceragen, Inc. (formerly Idera Pharmaceuticals, Inc.), a corporation organized under the laws of the state of Delaware (the “Company” or the “Issuer”), held directly by Messrs. Umari and El Zein, and Messrs. Umari and El Zein expressly disclaim beneficial ownership of any shares of Common Stock held directly by Pillar 6, Pillar Foundation and indirectly by Pillar GP.

Pillar 6 directly holds (a) 135,540 shares of Common Stock and (b) 45,114 Common Warrants (the “Common Warrants”), which are exercisable for shares of Common Stock. Pursuant to the terms of the Common Warrants, a blocker provision limits the number of Common Warrants exercisable for shares of Common Stock to the extent such exercise would allow the percentage of Common Stock held directly to exceed 19.99% (the “Blocker Provision”).

Pillar Foundation directly holds (a) 355,247 shares of Common Stock and (b) 35,687 Common Warrants, which are exercisable for shares of Common Stock. These Common Warrants are subject to the Blocker Provision.

All of the Common Warrants held by Pillar 6 and Pillar Foundation are currently exercisable, subject to the Blocker Provision, to the extent applicable.

Mr. El Zein directly holds 1,547 shares of Common Stock. Mr. Umari directly holds 164,894 shares of Common Stock.

- (2) The percentage of the class was calculated based on 8,423,504 shares of Common Stock outstanding as of June 29, 2023.

1.	NAMES OF REPORTING PERSONS		
	Pillar Partners Foundation, L.P.		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>		
3.	SEC USE ONLY		
4.	SOURCE OF FUNDS*		
	WC		
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)		
	<input type="checkbox"/>		
6.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Cayman Islands		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7.	SOLE VOTING POWER	
		0	
	8.	SHARED VOTING POWER	
		571,588 (1)	
	9.	SOLE DISPOSITIVE POWER	
		0	
	10.	SHARED DISPOSITIVE POWER	
		571,588 (1)	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	571,588 (1)		
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
	<input type="checkbox"/>		
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11		
	6.7% (2)		
14.	TYPE OF REPORTING PERSON		
	PN		

1.	NAMES OF REPORTING PERSONS		
	Pillar Invest Corporation		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>		
3.	SEC USE ONLY		
4.	SOURCE OF FUNDS*		
	AF		
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)		
	<input type="checkbox"/>		
6.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Cayman Islands		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7.	SOLE VOTING POWER	
		0	
	8.	SHARED VOTING POWER	
		571,588 (1)	
	9.	SOLE DISPOSITIVE POWER	
		0	
	10.	SHARED DISPOSITIVE POWER	
		571,588 (1)	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	571,588 (1)		
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
	<input type="checkbox"/>		
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11		
	6.7% (2)		
14.	TYPE OF REPORTING PERSON		
	PN		

1.	NAMES OF REPORTING PERSONS		
	Youssef El Zein		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>		
3.	SEC USE ONLY		
4.	SOURCE OF FUNDS*		
	AF		
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)		
	<input type="checkbox"/>		
6.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	France and Lebanon		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7.	SOLE VOTING POWER	
		1,547 (1)	
	8.	SHARED VOTING POWER	
		571,588 (1)	
	9.	SOLE DISPOSITIVE POWER	
		1,547 (1)	
	10.	SHARED DISPOSITIVE POWER	
		571,588 (1)	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	573,135 (1)		
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
	<input type="checkbox"/>		
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11		
	6.7% (2)		
14.	TYPE OF REPORTING PERSON		
	IN		

1.	NAMES OF REPORTING PERSONS		
	Abude Umari		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>		
3.	SEC USE ONLY		
4.	SOURCE OF FUNDS		
	AF		
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)		
	<input type="checkbox"/>		
6.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	France and Lebanon		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7.	SOLE VOTING POWER	
		164,894 (1)	
	8.	SHARED VOTING POWER	
		571,588 (1)	
	9.	SOLE DISPOSITIVE POWER	
		164,894 (1)	
	10.	SHARED DISPOSITIVE POWER	
		571,588 (1)	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	736,482 (1)		
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
	<input type="checkbox"/>		
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11		
	8.7% (2)		
14.	TYPE OF REPORTING PERSON		
	IN		

SCHEDULE 13D

Explanatory Note: This Amendment No. 16 to Schedule 13D (this “Amendment No. 16”) amends the Schedule 13D filed on November 14, 2011 (the “Original 13D”), as amended by Amendment No. 1 to Schedule 13D filed on November 16, 2012 (“Amendment No. 1”), Amendment No. 2 to Schedule 13D filed on June 5, 2013 (“Amendment No. 2”), Amendment No. 3 to Schedule 13D filed on October 9, 2013 (“Amendment No. 3”), Amendment No. 4 to Schedule 13D filed on October 17, 2016 (“Amendment No. 4”), Amendment No. 5 to Schedule 13D filed on July 25, 2019 (“Amendment No. 5”), Amendment No. 6 to Schedule 13D filed on May 7, 2020 (“Amendment No. 6”), Amendment No. 7 to Schedule 13D filed on August 17, 2020 (“Amendment No. 7”), Amendment No. 8 to Schedule 13D filed on December 30, 2020 (“Amendment No. 8”), Amendment No. 9 to Schedule 13D filed on April 1, 2021 (“Amendment No. 9”), Amendment No. 10 to Schedule 13D filed on June 7, 2021 (“Amendment No. 10”), Amendment No. 11 to Schedule 13D filed on June 24, 2022 (“Amendment No. 11”), Amendment No. 12 to Schedule 13D filed on July 1, 2022 (“Amendment No. 12”), Amendment No. 13 to Schedule 13D filed on October 5, 2022 (“Amendment No. 13”), Amendment No. 14 to Schedule 13D filed on January 30, 2023 (“Amendment No. 14”), and Amendment No. 15 to Schedule 13D filed on April 10, 2023 (together with the Original 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8, Amendment No. 9, Amendment No. 10, Amendment No. 11, Amendment No. 12, Amendment No. 13, Amendment No. 14, and Amendment No. 16 the “Schedule 13D”) and relates to the Common Stock. The principal executive offices of the Issuer are located at 505 Eagleview Blvd., Suite 212, Exton, PA 19341.

Except as specifically amended by this Amendment No. 16, the disclosure in the Schedule 13D remains in full force and effect. Capitalized terms used in this Amendment No. 16 but not otherwise defined shall have the meanings given to such terms in the Schedule 13D.

ITEM 5. Interest in Securities of the Issuer.

(a) — (b)

The following sets forth, as of the date of this Amendment No. 16, the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 8,423,504 shares of Common Stock outstanding at June 29, 2023.

Reporting Person	Amount beneficially owned	Percent of class	Sole power to vote or to direct the vote	Shared power to vote or to direct the vote	Sole power to dispose or to direct the disposition	Shared power to dispose or to direct the disposition
Pillar 6	571,588	6.7%	0	571,588	0	571,588
Pillar Foundation	571,588	6.7%	0	571,588	0	571,588
Pillar GP	571,588	6.7%	0	571,588	0	571,588
Abude Umari	736,482	8.7%	164,894	571,588	164,894	571,588
Youssef El Zein	573,135	6.7%	1,547	571,588	1,547	571,588

(c) Except as set forth in the table below, no transactions in the Common Stock were effected by the Reporting Persons during the past 60-day period.

Reporting Person	Date	Amount of Securities	Price per Share	Where and How Effected
Abude Umari	May 15, 2023	45,609	\$ 1.57	Acquired in the Open Market
Abude Umari	May 16, 2023	45,441	\$ 1.49	Acquired in the Open Market
Abude Umari	May 17, 2023	26,965	\$ 1.42	Acquired in the Open Market
Abude Umari	July 12, 2023	3,605	\$ 1.58	Sold in the Open Market
Abude Umari	July 13, 2023	2,213	\$ 1.54	Sold in the Open Market

(d) No persons other than the Reporting Persons and their investment clients have the right to participate in the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered hereby.

(e) Not Applicable.

ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Item 4 to this Schedule 13D is hereby amended to add the following:

As previously disclosed, Pillar Foundation was a party to a Warrant to Purchase Common Stock of the Company issued in July 2020 (the “July 2020 Warrant Agreement”). Pursuant to its terms, the July 2020 Warrant Agreement automatically expired on July 13, 2023, and as such, Pillar Foundation’s right to exercise up to 162,601 Common Warrants expired.

ITEM 7. Materials to be Filed as Exhibits.

Exhibit 99.1: Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

EXECUTED as a sealed instrument this 17th day of July, 2023.

PILLAR PHARMACEUTICALS 6, L.P.
CORPORATION

By: Pillar Invest Corporation, its general partner

By: /s/ Youssef El Zein
Name: Youssef El Zein
Title: Director

PILLAR PARTNERS FOUNDATION, L.P.

By: /s/ Youssef El Zein
Name: Youssef El Zein
Title: Director

PILLAR INVEST CORPORATION

By: /s/ Youssef El Zein
Name: Youssef El Zein
Title: Director

/s/ Abude Umari
Abude Umari

/s/ Youssef El Zein
Youssef El Zein

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Date: July 17, 2023

**PILLAR PHARMACEUTICALS 6, L.P.
CORPORATION**

By: Pillar Invest Corporation, its general partner

By: /s/ Youssef El Zein
Name: Youssef El Zein
Title: Director

PILLAR PARTNERS FOUNDATION, L.P.

By: /s/ Youssef El Zein
Name: Youssef El Zein
Title: Director

PILLAR INVEST CORPORATION

By: /s/ Youssef El Zein
Name: Youssef El Zein
Title: Director

/s/ Abude Umari
Abude Umari

/s/ Youssef El Zein
Youssef El Zein